New drug combo tested in fight against deadly brain cancer
NCT ID NCT03587038
Summary
This is an early-stage study to see if adding an experimental drug called OKN-007 to the standard treatment (temozolomide and radiation) is safe and tolerable for people newly diagnosed with an aggressive brain cancer called glioblastoma. The main goal is to find the highest dose patients can handle without severe side effects. Researchers will also track if the combination helps slow the cancer's growth and extend survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117, United States
Conditions
Explore the condition pages connected to this study.